Join our daily newsletter At The Bell to receive exclusive market insights
- Paradigm Biopharmaceuticals (PAR) sees a shake up to its leadership board, with CEO Paul Rennie transitioning from Managing Director to a non-executive role as Chairman
- In the non-executive role, Paul Rennie will focus on the direction of the company, working to enhance the strategic relationships
- Paradigm’s Chief Medical Officer, Dr Donna Skerrett, will assume the role of interim CEO
- A global executive search is now underway for Paradigm’s next CEO, with potential candidates already identified
- Paradigm Biopharmaceuticals last traded at $2.15 on November 19
Biopharmaceutical company, Paradigm Biopharmaceuticals (PAR) has seen a shakeup to its leadership board.
Paradigm’s CEO, Paul Rennie, is set to transition from his executive role as Managing Director to a non-executive role as Chairman, effective immediately.
In the non-executive role, Paul Rennie will focus on the direction of the company, working to enhance strategic relationships.
Paul Rennie said it has been a pleasure to have been the CEO and Managing Director of Paradigm Biopharmaceuticals.
“I look forward to my continued involvement with Paradigm in this new role – it is a very exciting period for Paradigm as it moves further into its global phase 3 pivotal trial in Osteoarthritis (which is a large market with poorly met needs),” he said.
Following this, Paradigm’s Chief Medical Officer, Donna Skerrett, will assume the role of interim CEO.
“Dr Skerrett is a very capable and talented person and knows the company very well,” Mr Rennie said.
“Her proven talents have gained the respect of the entire Paradigm team and will ensure a seamless transition.”
A global executive search is now underway for Paradigm’s next CEO, with a number of potential candidates already identified.
Paradigm Biopharmaceuticals last traded at $2.15 on November 19.
